Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
06
07
2021
pubmed:
6
8
2021
medline:
28
1
2022
entrez:
5
8
2021
Statut:
ppublish
Résumé
Infliximab, an anti-tumour necrosis factor (TNF)-α monoclonal antibody, has been approved in chronic inflammatory disease, including rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. This study aimed to investigate and characterise target-mediated drug disposition of infliximab and antigen mass turnover during infliximab treatment. In this retrospective cohort of 186 patients treated with infliximab for rheumatoid arthritis, Crohn's disease or ankylosing spondylitis, trough infliximab concentrations were determined from samples collected between weeks 0 and 22 after treatment initiation. Target-mediated pharmacokinetics of infliximab was described using target-mediated drug disposition modelling. Target-mediated elimination parameters were determined for rheumatoid arthritis and Crohn's disease, assuming ankylosing spondylitis with no target-mediated elimination. The quasi-equilibrium approximation of a target-mediated drug disposition model allowed a satisfactory description of infliximab concentration-time data. Estimated baseline TNF-α amounts were similar in Crohn's disease and rheumatoid arthritis (R0 = 0.39 vs 0.46 nM, respectively), but infliximab-TNF complex elimination was slower in Crohn's disease than in rheumatoid arthritis (k The present study is the first to quantify the influence of target antigen dynamics on infliximab pharmacokinetics. Target-mediated elimination of infliximab may be complex, involving a multi-scale turnover of TNF-α, especially in patients with Crohn's disease. Additional clinical studies are warranted to further evaluate and fine-tune dosing approaches to ensure sustained TNF-α inhibition.
Sections du résumé
BACKGROUND AND OBJECTIVE
Infliximab, an anti-tumour necrosis factor (TNF)-α monoclonal antibody, has been approved in chronic inflammatory disease, including rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. This study aimed to investigate and characterise target-mediated drug disposition of infliximab and antigen mass turnover during infliximab treatment.
METHODS
In this retrospective cohort of 186 patients treated with infliximab for rheumatoid arthritis, Crohn's disease or ankylosing spondylitis, trough infliximab concentrations were determined from samples collected between weeks 0 and 22 after treatment initiation. Target-mediated pharmacokinetics of infliximab was described using target-mediated drug disposition modelling. Target-mediated elimination parameters were determined for rheumatoid arthritis and Crohn's disease, assuming ankylosing spondylitis with no target-mediated elimination.
RESULTS
The quasi-equilibrium approximation of a target-mediated drug disposition model allowed a satisfactory description of infliximab concentration-time data. Estimated baseline TNF-α amounts were similar in Crohn's disease and rheumatoid arthritis (R0 = 0.39 vs 0.46 nM, respectively), but infliximab-TNF complex elimination was slower in Crohn's disease than in rheumatoid arthritis (k
CONCLUSIONS
The present study is the first to quantify the influence of target antigen dynamics on infliximab pharmacokinetics. Target-mediated elimination of infliximab may be complex, involving a multi-scale turnover of TNF-α, especially in patients with Crohn's disease. Additional clinical studies are warranted to further evaluate and fine-tune dosing approaches to ensure sustained TNF-α inhibition.
Identifiants
pubmed: 34351609
doi: 10.1007/s40262-021-01057-3
pii: 10.1007/s40262-021-01057-3
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antirheumatic Agents
0
Pharmaceutical Preparations
0
Tumor Necrosis Factor-alpha
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-154Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857–74.
doi: 10.1007/s40262-020-00874-2
Le Tilly O, Bejan-Angoulvant T, Paintaud G, et al. Letter to Dreesen et al. on their article “Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease”: a comprehensive review of infliximab population pharmacokinetic modelling publications. Br J Clin Pharmacol. 2020;2020:14554.
Berends SE, van Steeg TJ, Ahsman MJ, et al. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J Pharmacokinet Pharmacodyn. 2019;46:543–51.
doi: 10.1007/s10928-019-09652-5
Furuya Y, Ozeki T, Takayanagi R, et al. Theory based analysis of anti-inflammatory effect of infliximab on Crohn’s disease. Drug Metab Pharmacokinet. 2007;22:20–5. https://doi.org/10.2133/dmpk.22.20 .
doi: 10.2133/dmpk.22.20
pubmed: 17329907
Kimura K, Takayanagi R, Yokoyama H, et al. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn’s disease and rheumatoid arthritis. Rheumatol Int. 2012;32:145–50.
doi: 10.1007/s00296-010-1553-8
Kimura K, Yoshida A, Katagiri F, et al. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos. 2019;40:250–61.
doi: 10.1002/bdd.2198
Kimura K, Takayanagi R, Yokoyama H, et al. Theory-based analysis of the anti-inflammatory effect of TNF inhibitors on rheumatoid arthritis. Drug Metab Pharmacokinet. 2014;29:272–7. https://doi.org/10.2133/dmpk.dmpk-13-rg-090 .
doi: 10.2133/dmpk.dmpk-13-rg-090
pubmed: 24418824
MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990;81:301–5. https://doi.org/10.1111/j.365-2249.1990.tb03334.x .
doi: 10.1111/j.365-2249.1990.tb03334.x
pubmed: 2117510
pmcid: 1535044
Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913–7. https://doi.org/10.1136/gut.32.8.913 .
doi: 10.1136/gut.32.8.913
pubmed: 1885073
pmcid: 1378961
Schulz M, Dotzlaw H, Neeck G. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed Res Int. 2014;2014:24.
doi: 10.1155/2014/675108
Passot C, Pouw MF, Mulleman D, et al. Therapeutic drug monitoring of biopharmaceuticals may benefit from pharmacokinetic and pharmacokinetic-pharmacodynamic modeling. Ther Drug Monit. 2017;39:322–6.
doi: 10.1097/FTD.0000000000000389
Aubourg A, Picon L, Lecomte T, et al. A robust estimation of infliximab pharmacokinetic parameters in Crohn’s disease. Eur J Clin Pharmacol. 2015;71:1541–2.
doi: 10.1007/s00228-015-1942-8
Passot C, Mulleman D, Bejan-Angoulvant T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs. 2016;8:1407–16.
doi: 10.1080/19420862.2016.1216741
Ternant D, Passot C, Aubourg A, et al. Model-based therapeutic drug monitoring of infliximab using a single serum trough concentration. Clin Pharmacokinet. 2018;57:1173–84.
doi: 10.1007/s40262-017-0621-6
Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol. 2017;69:108–13.
doi: 10.1002/art.39841
Mulleman D, Chu Miow Lin D, Ducourau E, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit. 2010;32:232–6.
doi: 10.1097/FTD.0b013e3181cc6fef
Ternant D, Arnoult C, Pugniere M, et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J Immunol. 2016;196:607–13. https://doi.org/10.4049/jimmunol.1501780 .
doi: 10.4049/jimmunol.1501780
pubmed: 26685205
Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523–9. https://doi.org/10.1097/FTD.0b013e318180e300 .
doi: 10.1097/FTD.0b013e318180e300
pubmed: 18641542
Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169–74.
doi: 10.1097/01.ftd.0000189901.08684.4b
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.
doi: 10.1023/A:1014414520282
Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009;5:803–12. https://doi.org/10.1517/17425250902992901 .
doi: 10.1517/17425250902992901
pubmed: 19505189
Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4(Suppl. 2):S22–8. https://doi.org/10.1186/ar549 .
doi: 10.1186/ar549
pubmed: 12110154
pmcid: 3238217
Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41:329–37. https://doi.org/10.1093/rheumatology/41.3.329 .
doi: 10.1093/rheumatology/41.3.329
Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183–91. https://doi.org/10.2147/btt.009.3099 .
doi: 10.2147/btt.009.3099
pubmed: 19707407
pmcid: 2726073
Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–16. https://doi.org/10.1016/j.clim.2009.01.002 .
doi: 10.1016/j.clim.2009.01.002
pubmed: 19188093
Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol. 2007;374:1374–88. https://doi.org/10.1016/j.jmb.2007.10.034 .
doi: 10.1016/j.jmb.2007.10.034
pubmed: 17996896
Chen X, DuBois DC, Almon RR, et al. Interrelationships between infliximab and recombinant tumor necrosis factor-α in plasma using minimal physiologically based pharmacokinetic models. Drug Metab Dispos. 2017;45:790–7.
doi: 10.1124/dmd.116.074807
Buhl S, Dorn-Rasmussen M, Brynskov J, et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scand J Gastroenterol. 2020;55:884–90.
doi: 10.1080/00365521.2020.1786852
Deora A, Hegde S, Lee J, et al. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs. 2017;9:680–95.
doi: 10.1080/19420862.2017.1304869
Olesen CM, Coskun M, Peyrin-Biroulet L, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110–9.
doi: 10.1016/j.pharmthera.2016.01.001
Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–9. https://doi.org/10.1006/cyto.995.0029 .
doi: 10.1006/cyto.995.0029
pubmed: 7640345
Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–26. https://doi.org/10.1124/jpet.301.2.418 .
doi: 10.1124/jpet.301.2.418
pubmed: 11961039
Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;135:3972–7.
pubmed: 2999236
Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:137–44. https://doi.org/10.1007/BF00253968 .
doi: 10.1007/BF00253968
pubmed: 3664933
Greischel A, Zahn G. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. J Pharmacol Exp Ther. 1989;251:358–61.
pubmed: 2795465
Zahn G, Greischel A. Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats: dose dependence and influence of tumor necrosis factor beta. Arzneimittelforschung. 1989;39:1180–2.
pubmed: 2590273
Ternant D, Azzopardi N, Raoul W, et al. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58:169–87.
doi: 10.1007/s40262-018-0680-3
Thilagar S, Theyagarajan R, Sudhakar U, et al. Comparison of serum tumor necrosis factor-α levels in rheumatoid arthritis individuals with and without chronic periodontitis: a biochemical study. J Indian Soc Peridontal. 2018;22:116–21. https://doi.org/10.4103/jisp.jisp_362_17 .
doi: 10.4103/jisp.jisp_362_17
Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1208–15.
doi: 10.1136/ard.2011.153023
Tanaka Y, Oba K, Koike T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2020;79:94–102.
doi: 10.1136/annrheumdis-2019-216169
Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn. 2012;39:429–51.
doi: 10.1007/s10928-012-9260-6
Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78:118–28.
doi: 10.1111/bcp.12313
Eser A, Reinisch W, Schreiber S, et al. Increased induction infliximab clearance predicts early antidrug antibody detection. J Clin Pharmacol. 2021;61:224–33.
doi: 10.1002/jcph.1732
Buurman DJ, Maurer JM, Keizer RJ, et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42:529–39.
doi: 10.1111/apt.13299
Ternant D, Bejan-Angoulvant T, Passot C, et al. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015;54:1107–23.
doi: 10.1007/s40262-015-0296-9
Ait-Oudhia S, Ovacik MA, Mager DE. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs. 2017;9:15–28.
doi: 10.1080/19420862.2016.1238995
Ternant D, Mulleman D, Lauferon F, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2011;2011:1365–2125.
Edlund H, Steenholdt C, Ainsworth MA, et al. Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in Crohn’s disease is determined by their concentration. AAPS J. 2017;19:223–33.
doi: 10.1208/s12248-016-9989-8
Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946–64.
doi: 10.1016/j.clinthera.2011.06.002
Petitcollin A, Brochard C, Siproudhis L, et al. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. Clin Pharmacol Ther. 2019;106:605–15.
doi: 10.1002/cpt.1429
Ternant D, Picon L, Cartron G, et al. Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation. PAGE. 2019;28:abstract no. 9169. Available from: www.page-meeting.org/?abstract=9169 . Accessed 11 Jul 2021.